SCHEMBL569695

SCHEMBL569695

CC(C)n1ccc(Br)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31473623 0.77 MAP4K1 (0.32)
SCHEMBL22579526 0.76
SCHEMBL23229674 0.76 PGR (0.31)
SCHEMBL1085116 0.76 KDM4E (0.41)
SCHEMBL21165960 0.73 DYRK1A (0.38)
SCHEMBL20762092 0.73 DYRK1A (0.38)
SCHEMBL30730193 0.72 ALDH1A1 (0.34)
SCHEMBL20509931 0.71
SCHEMBL10197118 0.71
SCHEMBL1872147 0.71 DYRK1A (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090348-A1 THE USE OF SON OF SEVENLESS (SOS) INHIBITOR COMPOUNDS SUCH AS 7-SUBSTITUTED BENZOFURANS TO TREAT CANCER Mirati Therapeutics, Inc. (US) 2026-04-30 WO disclosed
US-12459923-B2 Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2025-11-04 US disclosed
EP-4619406-A1 TRICYCLIC COMPOUNDS Schrödinger, Inc. (US) 2025-09-24 EP disclosed
EP-4269400-B1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE SA (PL) 2025-07-09 EP disclosed
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 EP disclosed
CN-119730846-A Kinase modulators and methods of use thereof 神经元23公司 2025-03-28 CN disclosed
EP-3787621-B1 TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARM INC (US) 2024-12-18 EP disclosed
WO-2023244788-A9 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-09-12 WO disclosed
US-20240270759-A1 Preparation of SHP2 phosphatase inhibitors and its applications YA THERAPEUTICS INC (CN) 2024-08-15 US disclosed
US-20240228464-A9 TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARM INC (US) 2024-07-11 US disclosed
CN-112312905-A Tetrazole-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof 英安塔制药有限公司 2021-02-02 CN disclosed
CN-111630054-A Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors 奥瑞生物药品公司 2020-09-04 CN disclosed
US-20190337923-A1 TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2019-11-07 US disclosed
CN-106132952-B Terazololine-one compound and its application 住友化学株式会社 2019-04-16 CN disclosed
EP-2601192-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2017-03-01 EP disclosed
CN-103201262-B Autotaxin inhibitors and application thereof AMIRA PHARMACEUTICALS, INC. (US) 2016-06-01 CN disclosed
CN-104059066-A Diazacarbazoles And Methods Of Use GENENTECH INC 2014-09-24 CN disclosed
CN-103958500-A Protein kinase inhibitors ORION CORP 2014-07-30 CN disclosed
EP-2601192-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2013-06-12 EP disclosed
WO-2012018909-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-09 WO disclosed